🔗 Share this article America and Britain Conclude Duty-Free Arrangement on Prescription Drugs. Representative image of medicine shipments. The UK and US have finalized a key bilateral deal that will guarantee no import taxes on UK drug exports entering the US market. Agreement Details of the Accord As part of the deal, the UK has agreed to boost spending on pharmaceuticals through the NHS. This move ensures that import taxes on these key products will stay at zero for a timeframe of the next three years. This deal comes after earlier statements to hike import taxes on patented pharmaceutical products, with increases floated reaching one hundred percent. "This deal with the United Kingdom bolsters the international landscape for cutting-edge drugs and introduces much-needed equity to American-British pharmaceutical trade," a release declared. Trade Impact Drugs are one of the UK's biggest export categories to the United States, which is easily the largest market for major British pharmaceutical firms. Trade data show that in the year to the end of last September, the UK exported pharmaceutical products worth billions to the US. This amount made up a significant portion of all goods exports in that span. "This guarantee secures work, stimulates investment and facilitates the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated. Specific British Pledges The deal involves several specific pledges from the UK: Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by a quarter. Higher Drug Budget: There is a aim to increase total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade. Payback Limit: The sum manufacturers must return to the NHS to stay within budget will be limited at 15%. Last year, refunds exceeded 20%. Industry Background The deal follows a long-running row between the sector and the ministers over spending levels and regulatory access. These tensions were intensified by assertions that US consumers were charged significantly more for the same drugs than consumers in the UK and Europe. Recently, several significant manufacturing plans in the UK have been paused or abandoned, while substantial funding commitments have been announced toward US facilities. One official acknowledged that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had declined as a share of its overall budget over the past decade.
Representative image of medicine shipments. The UK and US have finalized a key bilateral deal that will guarantee no import taxes on UK drug exports entering the US market. Agreement Details of the Accord As part of the deal, the UK has agreed to boost spending on pharmaceuticals through the NHS. This move ensures that import taxes on these key products will stay at zero for a timeframe of the next three years. This deal comes after earlier statements to hike import taxes on patented pharmaceutical products, with increases floated reaching one hundred percent. "This deal with the United Kingdom bolsters the international landscape for cutting-edge drugs and introduces much-needed equity to American-British pharmaceutical trade," a release declared. Trade Impact Drugs are one of the UK's biggest export categories to the United States, which is easily the largest market for major British pharmaceutical firms. Trade data show that in the year to the end of last September, the UK exported pharmaceutical products worth billions to the US. This amount made up a significant portion of all goods exports in that span. "This guarantee secures work, stimulates investment and facilitates the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated. Specific British Pledges The deal involves several specific pledges from the UK: Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by a quarter. Higher Drug Budget: There is a aim to increase total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade. Payback Limit: The sum manufacturers must return to the NHS to stay within budget will be limited at 15%. Last year, refunds exceeded 20%. Industry Background The deal follows a long-running row between the sector and the ministers over spending levels and regulatory access. These tensions were intensified by assertions that US consumers were charged significantly more for the same drugs than consumers in the UK and Europe. Recently, several significant manufacturing plans in the UK have been paused or abandoned, while substantial funding commitments have been announced toward US facilities. One official acknowledged that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had declined as a share of its overall budget over the past decade.